690265-96-4

Basic information

• Product Name: methanesulfonic acid-2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy} ethyl ester
• Synonyms: methanesulfonic acid-2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy} ethyl ester
• CAS NO: 690265-96-4
• Molecular Weight: 427.908
• Mol File: 690265-96-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methanesulfonic acid-2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy} ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: methanesulfonic acid-2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy} ethyl ester(690265-96-4)
• EPA Substance Registry System: methanesulfonic acid-2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy} ethyl ester(690265-96-4)

Safety Data

• Hazardous Substances Data: 690265-96-4(Hazardous Substances Data)

Upstream product

• 690265-95-3 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethanol 
• 124-63-0 methanesulfonyl chloride 
• 690264-31-4 5-(4-chloro-phenyl)-2-ethynyl-pyridine 
• 29639-77-8 2-(4-iodophenoxy)ethanol 
• 111770-80-0 3-bromo-6-(trimethylsilylethynyl)pyridine 
• 690264-30-3 5-(4-chloro-phenyl)-2-trimethylsilanylethynyl-pyridine 

Downstream Products

• 866928-31-6 1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-4-trifluoromethyl-piperidin-4-ol 

Relevant articles and documents

Design, synthesis and evaluation of MCH receptor 1 antagonists - Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414

Abstract Despite recent approvals of anti-obesity drugs there is still a high therapeutic need for alternative options with higher efficacy in humans. As part of our MCH-R1 antagonist program for the treatment of obesity, a series of biphenylacetamide HTS

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.